Physician profile
Esther Smith
NPI 1932304664
$1,321.22
in general payments reported to CMS, 2019-2025
26 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $107 · 2022: $26.82 · 2023: $129 · 2024: $291 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.87 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $142.10 | 2019-2024 | Lo Loestrin Fe, Orilissa |
| Exeltis, USA INC. | $139.10 | 2019-2025 | Slynd |
| Astellas Pharma US INC | $111.05 | 2020-2025 | Veozah |
| Novo Nordisk INC | $105.48 | 2019-2025 | Wegovy |
| Coopersurgical, INC. | $94.18 | 2023-2025 | Paragard T 380a, Paragard T 380a |
| Merck Sharp & Dohme LLC | $84.99 | 2019-2020 | |
| Hologic Sales and Service, LLC | $59.90 | 2020-2025 | Aptima, Thinprep 2000 Processor |
| Bayer Healthcare Pharmaceuticals INC. | $52.92 | 2019-2025 | |
| Amgen INC. | $49.43 | 2019-2024 | Evenity, Prolia |
| Organon LLC | $47.28 | 2023-2024 | Nexplanon |
| Roche Diagnostics Corporation | $46.38 | 2019 | |
| Vivus LLC | $42.30 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.06 | 2019 | |
| Amag Pharmaceuticals, INC. | $39.47 | 2019 | |
| Meditrina | $39.09 | 2023-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $38.54 | 2025 | |
| Sanofi Pasteur INC. | $32.26 | 2025 | |
| Pfizer INC. | $30.82 | 2023 | |
| Mimedx Group, INC. | $20.67 | 2025 | |
| Minerva Surgical, INC | $20.67 | 2025 | |
| Greenwich Biosciences, INC. | $20.55 | 2019 | |
| Dentsply Sirona INC | $16.15 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $13.07 | 2019 | |
| Therapeuticsmd, INC. | $11.95 | 2019 | |
| Lupin INC. | $10.94 | 2019 | |
| Boston Scientific Corporation | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esther Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.